Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351598
Status:
COMPLETED
Last Update Posted:
2014-08-04
First Post:
2006-07-11
Brief Title:
Lung Tumour Volume Database
Sponsor:
Trans Tasman Radiation Oncology Group
Organization:
Trans Tasman Radiation Oncology Group
Study Overview
Official Title:
Tumour Volume as an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer - A Protocol for a Prospective Database
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main aim is to determine in patients with locoregional non-small cell lung cancer NSCLC treated by definitive radiotherapy the influence on survival of the volume of primary tumour as measured from CT imaging after adjusting for the effect of the current TNM staging system and other known prognostic factors especially ECOG performance and weight loss
Detailed Description:
Patients with locoregional non small cell lung cancer are registered on study after tumour volumes are outlined by a radiologist and prior to the commencement of any treatment
All patients must have recorded the volume of disease in the primary tumour and of involved nodes 1 cm diameter as measured from a CT scan performed according to a standard set of conditions
Following registration patients are treated with Definitive radiotherapy with or without chemotherapy Follow-up will occur with the collection of a minimum amount of data every 12 months from the date of registration on study
Quality Assurance procedures will be implemented with each site that participates in the study
All patients must have recorded the volume of disease in the primary tumour and of involved nodes 1 cm diameter as measured from a CT scan performed according to a standard set of conditions
Following registration patients are treated with Definitive radiotherapy with or without chemotherapy Follow-up will occur with the collection of a minimum amount of data every 12 months from the date of registration on study
Quality Assurance procedures will be implemented with each site that participates in the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None